XTX Topco Ltd Buys New Stake in Bicycle Therapeutics plc (NASDAQ:BCYC)

XTX Topco Ltd purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) in the second quarter, Holdings Channel.com reports. The firm purchased 10,177 shares of the company’s stock, valued at approximately $206,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Baker BROS. Advisors LP raised its position in shares of Bicycle Therapeutics by 176.1% during the 1st quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock worth $123,076,000 after acquiring an additional 3,152,433 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Bicycle Therapeutics by 53.6% during the 4th quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock worth $27,771,000 after buying an additional 536,000 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Bicycle Therapeutics by 13.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock worth $25,869,000 after buying an additional 121,613 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Bicycle Therapeutics by 0.6% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock valued at $17,975,000 after buying an additional 4,976 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after buying an additional 124,809 shares during the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BCYC shares. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a research report on Monday, September 16th. B. Riley downgraded Bicycle Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $33.00 to $28.00 in a report on Wednesday, August 7th. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research note on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.56.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,194 shares of Bicycle Therapeutics stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $19.64, for a total value of $62,730.16. Following the sale, the chief executive officer now owns 384,076 shares of the company’s stock, valued at approximately $7,543,252.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 4,555 shares of company stock valued at $89,460 over the last ninety days. Corporate insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $23.21 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. The business has a 50 day simple moving average of $23.49 and a 200-day simple moving average of $22.95. Bicycle Therapeutics plc has a 12 month low of $12.54 and a 12 month high of $28.20. The stock has a market capitalization of $992.90 million, a PE ratio of -5.22 and a beta of 0.90.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.33. The company had revenue of $9.36 million during the quarter, compared to the consensus estimate of $6.13 million. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The company’s revenue was down 17.9% on a year-over-year basis. Equities analysts predict that Bicycle Therapeutics plc will post -3.17 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.